Drug Trial Radar · NCT01423500
ALL-SCT BFM International- HSCT in Children and Adolescents With ALL
Last checked: Nov 20, 2026Latest source record: Jun 26, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
405
Planned (sponsor's estimate)
Start
Jan 2007
Primary completion
Sep 2011
Study completion Sep 2016
Sponsor
- Lead sponsor
- St. Anna KinderkrebsforschungAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 26, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 3 months, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
With this protocol the ALL-SCT BFM international study group wants * to evaluate whether hematopoietic stem cell transplantation (HSCT) from matched family or unrelated donors (MD) is equivalent to the HSCT from matched sibling donors (MSD). * to evaluate the efficacy of hematopoietic stem cell transplantation (HSCT)from mismatched family or unrelated donors (MMD) as compared to HSCT from matched sibling donors or matched donors. * to determine whether therapy has been carried out according to the main HSCT protocol recommendations. The standardisation of the treatment options during HSCT from different donor types aims at the achievement of an optimal comparison of survival after HSCT with survival after chemotherapy only. * to prospectively evaluate and compare the incidence of acute and chronic Graft-versus-Host-Disease (GvHD) after HSCT from matched sibling donor (MSD), from matched donor (MD) and from mismatched donor (MMD).
Conditions
- Lymphoblastic Leukemia, Acute, Childhood;
Interventions
VP16Drug
patients with MSD receive as conditioning VP16 60mg/kg/d on day -3
TBIRadiation
patients with a MSD receive TBI (12Gy in 6 fractions) as conditioning
VP16, ATGDrug
patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
TBIRadiation
patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions)
Fludarabine, OKT3, Treosulfan, ThiotepaDrug
patients with a MMD (haploidentical or cord blood) receive Fludarabine 30mg/m²/d on day -9 to -5, ATG fresenius 20mg/kg/d on day -3,-2,-1, Treosulfan 14g/m²/d on day -7 to -5 and Thiotepa 2x5mg/kg/d on day -4
VP16, ATGDrug
patients with MMD-transplantation (8/10)receive VP16 60mg/kg/d on day -4, ATG from day -3 to day-1 20mg/kg/d
TBIRadiation
patients with a MMD-transplantation (8/10) receive 12 Gy in 6 fractions
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event free survivalTime frame: 10 years
Locations
24 sites in 11 countries. Site status is shown where the registry gives one.
Universitätsklinik für Kinder- und Jugendheilkunde, Klin. Abt. f. Hämato-Onkologie
Graz, Austria
Universitätsklinik für Kinder- und Jugendheilkunde
Innsbruck, Austria
St. Anna Children's Hospital
Vienna, Austria
Department of Paediatric Haematology and Oncology HSCT-Unit
Prague, Czechia
Pediatric Clinic II, Rigshospitalet
Copenhagen, Denmark
Pediatric Immuno-Hematology Unit Robert Debré Hospital
Paris, France
Rambam Medical Center
Haifa, Israel
Schneider Children's Medical Center of Israel
Petah Tikva, Israel
Clinica Pediatrica dell'Universita di Milano Bicocca, Hospitale San Gerardo
Monza, Italy
Leiden University Hospital
Leiden, Netherlands
Radboud University - Nijmegen Medical Centre
Nijmegen, Netherlands
Department of Paediatric Haematology and Oncology, Wilhelmina Children's Hospital
Utrecht, Netherlands
University Hospital, Collegium Medicum UMK, Pediatric Hematology and Oncology
Bydgoszcz, Poland
Department of Transplantation, University Children's Hospital
Cracow, Poland
Children's University Hospital - Hematology - Oncology
Lublin, Poland
Department of Pediadric Oncology, Hematology and Transplantology, University of Medical Sciences
Poznan, Poland
Wroclaw Medical University, Dept. of Children Hematology and Oncology
Wroclaw, Poland
Department of Pediatric Bone Marrow Transplantation Unit, University Childrens´ Hospital
Bratislava, Slovakia
Department of Pediatric Oncology, Lund University Hospital
Lund, Sweden
Department of Pediatrics, Gülhane Military Medical Academy
Ankara, Turkey (Türkiye)
Dept. of Paediatrics - BMT Unit, School of Medicine, University of Ankara
Ankara, Turkey (Türkiye)
Department of Pediatric Hematology-Oncology and Pediatric Stem Cell Transplantation, Akdeniz University School of Medicine
Antalya, Turkey (Türkiye)
Department of Pediatric Hematology, Oncology and BMT, Istanbul School of Medicine
Istanbul, Turkey (Türkiye)
Pediatric BMT Centre, Ege University
Izmir, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.